Clinical Trials · Episode
Andreas Beust — How a Small CRO Covers the Globe Without Growing
In this episode of the Pharma Prescribed Podcast, host Adam Walker sits down with Andreas Beust — CEO and Managing Director of GCP Service International in Bremen and President of ACROS, the Association of International CROs — to answer a deceptively simple question: how does a small CRO cover the globe without growing into something large, rigid and expensive? Andreas makes complex things accessible, which is his stated mission. He walks through the ACROS alliance model, the succession decision that moved him from the biostatistics desk to the CEO's office, what he looks for when hiring, and where AI genuinely helps in clinical trials — and where it does not.
Chapters
- 0:00Intro
- 0:35Meet Andreas Beust
- 3:00From the biostats desk to CEO
- 7:00Podcasting, curiosity and listening first
- 11:00Breaking into clinical research
- 16:00Advice for young talent
- 21:00Hiring for attitude
- 23:00Leading without ego
- 26:00A flexibility mindset
- 27:00Building the ACROS alliance
- 30:00The presidency and the mission
- 35:00A communal growth model
- 37:00AI in clinical trials — a reality check
- 42:00Compliance, costs and human in the loop
- 44:00Hope amid uncertainty
- 46:00Quickfire round
- 50:00Final takeaways
Key insights
Grow together, not bigger
ACROS brings together ten similarly sized, like-minded CROs across the US, Europe, the Middle East, India, China and Australia. Once a partner joins, their country is off-limits to the others, so members refer rather than compete — enabling global delivery without headcount sprawl.
Global reach through trusted partners
Twenty concurrent studies across Spain, Italy and Portugal can run through a single trusted partner, giving smaller sponsors a route to multi-country trials that large CROs often price out of reach.
AI: overpromise, modest real gains
Andreas is candid that much of the AI pitch is overpromise and underdeliver, with per-seat licence fees no small or mid-size company can absorb. The real gains today are in medical writing, programming and knowledge capture — always human in the loop.
Succession planned early
His predecessor started looking for a successor before turning 50, on the view that clinical research moves too fast to leave leadership continuity to chance.
Discomfort drives growth
Curiosity, listening first and deliberately stepping into the shop window of the unknown are what he credits for career growth — alongside hiring for attitude and leading without ego.
Newsletter issue
Pull back the curtain
CEO of GCP-Service International on the unlikely path from the biostats desk to the top job, why communication is the skill that sets scientists apart, and making an opaque industry more accessible.
The written companion to this conversation with Andreas Beust. Browse the newsletter archive
Loading preview…
Full transcript
Edited for readability. Speaker labels preserved. Click to collapse.Click to expand.
Full transcript
Edited for readability. Speaker labels preserved. Click to collapse.Click to expand.
Episode Overview
Adam Walker:Andreas Beust is CEO and Managing Director of GCP Service International, a Bremen-based CRO working across medicinal products, medical devices and in vitro diagnostics. He is also President of ACROS — the Association of International CROs — and a guest lecturer at the University of Bremen.
Andreas started on the biostatistics desk and now runs the company, elected by a leader who — not yet 50 — went looking for a successor because clinical research moves too fast to leave succession to chance.
The ACROS Model
Ten similarly sized, like-minded CROs from the US to Europe, the Middle East, India, China and Australia agree that once a partner joins, their country is off-limits to the others. That lets a small CRO run trials globally — 20 concurrent studies across Spain, Italy and Portugal through one trusted partner — without becoming the kind of large, rigid, expensive organisation that cannot serve smaller sponsors.
A Reality Check on AI
Andreas is refreshingly frank on AI: a lot of overpromise and underdeliver, quarter-of-a-million-per-seat licence fees that no small or mid-size company can pay, and real but modest gains in medical writing, programming and knowledge capture — always with a human in the loop.
Breaking in and Growing
On careers, he is honest about the thing that actually drives growth: discomfort. Curiosity, listening first, hiring for attitude, leading without ego, and putting yourself in the shop window of the unknown.
A full written transcript for this episode is being prepared and will be published here shortly.